Janux Therapeutics, Inc. (JANX): who owns it and who trades it
As of Nov 16, 2026, JANX insiders reported 10 open-market sales worth $457K and no purchases in the last 12 months, with 24% of the sale value made under pre-set 10b5-1 plans. The largest seller was Andrew Hollman Meyer (Chief Business Officer), with $136K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Janux Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns JANX
194 funds and institutions reported JANX shares worth $951M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 18.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 11.19M | 18.35% | $172M | No change |
| BlackRock, Inc. | 6.13M | 10.06% | $94.2M | +13% |
| Prosight Management, LP | 3.80M | 6.24% | $58.4M | +7% |
| State Street Corp | 3.00M | 4.93% | $46.2M | +22% |
| FMR LLC (Fidelity) | 2.41M | 3.96% | $37.1M | -5% |
| Federated Hermes, Inc. | 2.35M | 3.86% | $36.1M | +4241% |
| Point72 Asset Management, L.P. | 1.99M | 3.27% | $30.6M | +72% |
| Vanguard Capital Management LLC | 1.86M | 3.05% | $28.5M | +3% |
| TCG Crossover Management, LLC | 1.79M | 2.93% | $27.5M | No change |
| Alyeska Investment Group, L.P. | 1.65M | 2.70% | $25.3M | +3% |
| Nantahala Capital Management, LLC | 1.62M | 2.66% | $24.9M | +100% |
| Wellington Management Group LLP | 1.51M | 2.47% | $23.2M | -6% |
| Vanguard Portfolio Management LLC | 1.33M | 2.18% | $20.4M | +3% |
| Two Sigma Investments, LP | 1.21M | 1.98% | $18.5M | +940% |
| Geode Capital Management, LLC | 1.20M | 1.97% | $18.5M | +5% |
| Citadel Advisors LLC | 1.20M | 1.97% | $18.4M | +241% |
| Algert Global LLC | 1.11M | 1.82% | $17.1M | +151% |
| D. E. Shaw & Co., Inc. | 1.10M | 1.80% | $16.8M | +1014% |
| Goldman Sachs Group Inc | 952,675 | 1.56% | $14.6M | +58% |
| Bank of America Corp | 910,460 | 1.49% | $14M | +14% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, JANX insiders reported $0 of open-market purchases and $457K of sales. 24% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. | Sale | 4,059 | $14.03 | $56.9K | Form 4 |
| May 11, 2026 | Maria Dobek | Vice president | Sale | 2,038 | $14.17 | $28.9K | Form 4 |
| Jan 2, 2026 | Andrew Hollman Meyer | Chief Business Officer | Sale | 1,879 | $13.73 | $25.8K | Form 4 |
| Jan 2, 2026 | Thomas DiRaimondo | Chief Scientific Officer | Sale | 2,505 | $13.73 | $34.4K | Form 4 |
| Jan 2, 2026 | David Alan Campbell | CEO | Sale | 8,072 | $13.73 | $111K | Form 4 |
| Jan 2, 2026 | Charles M. Winter | Chief Technical Officer | Sale | 2,401 | $13.73 | $33K | Form 4 |
| Jan 2, 2026 | Zachariah McIver | Chief Medical Officer | Sale | 2,714 | $13.73 | $37.3K | Form 4 |
| Jan 2, 2026 | Maria Dobek | Vice president | Sale | 1,462 | $13.73 | $20.1K | Form 4 |
| Dec 1, 2025 | Andrew Hollman Meyer | Chief Business Officer | Sale plan | 633 | $33.52 | $21.2K | Form 4 |
| Dec 1, 2025 | Andrew Hollman Meyer | Chief Business Officer | Sale plan | 2,700 | $32.85 | $88.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Andrew Hollman Meyer | Chief Business Officer | – | $136K | Jan 2, 2026 |
| David Alan Campbell | President and CEO, Director | – | $111K | Jan 2, 2026 |
| Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | – | $56.9K | Jun 2, 2026 |
| Maria Dobek | Vice President, Accounting | – | $49K | May 11, 2026 |
| Zachariah McIver | Chief Medical Officer | – | $37.3K | Jan 2, 2026 |
| Thomas DiRaimondo | Chief Scientific Officer | – | $34.4K | Jan 2, 2026 |
| Charles M. Winter | Chief Technical Officer | – | $33K | Jan 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
JANX short interest
Moderate short interest. 8.7% of JANX shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 32%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.33M JANX shares were sold short, 8.7% of the shares outstanding, up 0.1% from the report before. At the average daily volume of 667,598 shares, buying them all back would take about 8.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.33M | 8.72% | +0% | 667,598 | 8.0 |
| Oct 15, 2026 | 5.33M | 8.71% | -6% | 859,874 | 6.2 |
| Sep 30, 2026 | 5.68M | 9.30% | -4% | 969,533 | 5.9 |
| Sep 15, 2026 | 5.89M | 9.64% | -3% | 999,885 | 5.9 |
| Aug 31, 2026 | 6.06M | 9.92% | -8% | 776,426 | 7.8 |
| Aug 14, 2026 | 6.63M | 10.84% | +12% | 607,942 | 10.9 |
| Jul 31, 2026 | 5.92M | 9.71% | -8% | 765,256 | 7.7 |
| Jul 15, 2026 | 6.45M | 10.58% | -9% | 1.00M | 6.4 |
| Jun 30, 2026 | 7.11M | 11.66% | -7% | 1.98M | 3.6 |
| Jun 15, 2026 | 7.62M | 12.49% | -6% | 694,792 | 11.0 |
| May 29, 2026 | 8.09M | 13.27% | +3% | 1.18M | 6.8 |
| May 15, 2026 | 7.83M | 12.83% | -1% | 810,461 | 9.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Janux Therapeutics company events
Janux Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 23, 2026AnnouncementWilliam Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Company’s Change in Control and Severance Benefit Plan (a copy of which is filed as Exhibit 10.12… Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 28, 2026LeadershipIn order to achieve a more equal balance of membership among the three classes of directors on the Board of Directors of Janux Therapeutics, Inc., the Board determined that one of its members should be reclassified from Class III (with a term expiring at the Company’s 2027 Annual Meeting of… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 22, 2026AgreementEntry into Material Definitive Agreement. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Janux Therapeutics financials
Famous investors that hold JANX
4 of the 50 well-known investors we track reported holding JANX in their latest 13F filing. The largest position is Steve Cohen's, worth $27.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.58M | $27.3M | 0.0% | -21% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 496,535 | $8.6M | 0.0% | -59% |
| Israel Englander · Millennium Management | Q3 2026 | 219,110 | $3.8M | 0.0% | -57% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 23,307 | $403K | 0.0% | -17% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named JANX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | W. Lawrence Hawkins | 13G/A | 5.2% |
| Nov 13, 2026 | W. Lawrence Hawkins | 13G/A | 5.2% |
Questions about Janux Therapeutics, Inc. (JANX) stock
Who owns the most JANX stock?
The largest reported owner of Janux Therapeutics, Inc. (JANX) is Ra Capital Management, L.P., with 18.3% of the company. In total, 194 funds and institutions reported holding JANX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are JANX insiders buying or selling?
In the last 12 months, JANX insiders reported no open-market purchases and 10 sales worth $457K. The latest trade was on Jun 2, 2026. See every trade.
What is the short interest in JANX?
As of Oct 30, 2026, 5.33M JANX shares were sold short, 8.7% of the shares outstanding, up 0.1% from the report before. At the average daily volume of 667,598 shares, buying them all back would take about 8.0 trading days (days to cover). See the history.
Which famous investors hold JANX?
4 of the 50 well-known investors we track reported JANX in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $27.3M. See all holders.
Executive pay
Janux Therapeutics's chief executive was paid a total of $13.5M for the year ended Dec 31, 2025, up 50% from $9M the year before. In the last 12 months, Janux Therapeutics's executives and directors bought no stock on the open market and sold $457K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.